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By focusing on molecular and cellular changes that are
up regulated in cancer, targeted agents may have less
severe side effects compared with conventional che-
motherapy. However, many of these signaling pathways
also exist in healthy cells and targeted therapies can
therefore result in specific complications [1-3].
The spectrum of toxicity encountered with the tar-
geted agents includes fatigue, skin rash and mucositis,
eye, cardiac and muscle toxicity, drug-induced intersti-
tial lung disease (DILD), posterior reversible encephalo-
pathy syndrome (PRES) and a wide spectrum of gastro-
intestinal complications. Nephrotoxic effects such as
proteinuria, nephrotic syndrome or hypertension are
also seen with agents such as VEGFR or mTOR
inhibitors.
The DILD imaging appearances encompass a range of
patterns including nonspecific ground-glass opacity with
and without interlobular septal thickening, multifocal
consolidations with or without traction bronchiectasis,
flitting subcentimetre nodules with or without ground
glass halo, bronchiolitis and pulmonary fibrosis or
pleural effusions [4]. Acute respiratory distress syn-
drome (ARDS) has also been described. The EGFR inhi-
bitors related DILD is an important challenge for their
use in lung carcinoma especially in patients with preex-
isting pulmonary fibrosis. Up to one-sixth of patients
taking mammalian target of rapamycin (mTOR) inhibi-
tors get a reversible interstitial pneumonitis [5].
Posterior reversible encephalopathy syndrome (PRES)
is an uncommon complication (incidence < 0.1%) of
VEGF/VEGFR pathway therapy. Most patients recover
fully with discontinuation of the causative agent and
supportive management of hypertension and seizures
[6]. Intra-cerebral bleeding has also been described with
anti-VEGF agents, especially in tumours with a strong
hemorrhagic tendency, such as renal-cell carcinoma. On
imaging, there is usually symmetrical vasogenic oedema
in the occipital and parietal regions. However, PRES can
be found in a non-posterior distribution, occurring at
watershed areas of vascular territories, including the
frontal, inferior temporal, cerebellar and brainstem
areas.
Increases of creatine kinase (CK) are amongst the
most common grade 3-4 toxicity treatment-related
adverse events of the Mitogen-activated protein kinase
(MEK) inhibitors, although most patients are asympto-
matic. Symptoms of CK increase include muscle weak-
ness and myalgia. The true significance especially of
asymptomatic CK increases is still unknown. An associa-
tion between CK elevation and skin rash of novel tar-
geted agents in phase I trials, possibly due to increased
CK-BB (brain and skin) expression of keratinocytes was
reported by Moreno Garcia et al [7].
With the continuous increase in the use of anti-cancer
targeted therapies, it is important for the radiologist to
be familiar with the clinical and treatment history and
associated complications that may occur, in order to
accurately identify drug-related complications and differ-
entiate them from disease progression.
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